Growth Metrics

ImmunityBio (IBRX) Cost of Revenue (2025)

ImmunityBio (IBRX) has disclosed Cost of Revenue for 1 consecutive years, with $382000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue changed N/A to $382000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $753000.0, a N/A change, with the full-year FY2025 number at $753000.0, changed N/A from a year prior.
  • Cost of Revenue was $382000.0 for Q4 2025 at ImmunityBio, up from $177000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $382000.0 in Q4 2025 to a low of $58000.0 in Q1 2025.